CA2588949A1 - Compounds with mixed pde-inhibitory and .beta.-adrenergic antagonist or partial agonist activity for treatment of heart failure - Google Patents

Compounds with mixed pde-inhibitory and .beta.-adrenergic antagonist or partial agonist activity for treatment of heart failure Download PDF

Info

Publication number
CA2588949A1
CA2588949A1 CA002588949A CA2588949A CA2588949A1 CA 2588949 A1 CA2588949 A1 CA 2588949A1 CA 002588949 A CA002588949 A CA 002588949A CA 2588949 A CA2588949 A CA 2588949A CA 2588949 A1 CA2588949 A1 CA 2588949A1
Authority
CA
Canada
Prior art keywords
compound
radicals
group
propoxy
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002588949A
Other languages
English (en)
French (fr)
Inventor
Malcolm George Taylor
Burkhard Klenke
Peter D. Suzdak
Reza Mazhari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Artesian Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2588949A1 publication Critical patent/CA2588949A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002588949A 2004-11-30 2005-11-08 Compounds with mixed pde-inhibitory and .beta.-adrenergic antagonist or partial agonist activity for treatment of heart failure Abandoned CA2588949A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63159804P 2004-11-30 2004-11-30
US60/631,598 2004-11-30
PCT/US2005/040586 WO2006060127A2 (en) 2004-11-30 2005-11-08 COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE

Publications (1)

Publication Number Publication Date
CA2588949A1 true CA2588949A1 (en) 2006-06-08

Family

ID=36218314

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002588949A Abandoned CA2588949A1 (en) 2004-11-30 2005-11-08 Compounds with mixed pde-inhibitory and .beta.-adrenergic antagonist or partial agonist activity for treatment of heart failure

Country Status (5)

Country Link
US (1) US20080090827A1 (enExample)
EP (1) EP1830852A2 (enExample)
JP (1) JP2008521806A (enExample)
CA (1) CA2588949A1 (enExample)
WO (1) WO2006060127A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
CA2658821C (en) 2006-07-25 2014-10-21 Cephalon, Inc. Pyridizinone derivatives and uses thereof to treat diseases, disorders and/or conditions that may be mediated or modulated by inhibition of h3 receptors
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
JP2010523579A (ja) * 2007-04-02 2010-07-15 インスティテュート フォア ワンワールド ヘルス Cftr阻害剤化合物およびそれらの使用
EP2702987A1 (en) 2008-11-25 2014-03-05 Boehringer Ingelheim Vetmedica GmbH Phosphodiesterase type III (PDE III) inhibitors or Ca2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
ES2924478T3 (es) 2012-03-15 2022-10-07 Boehringer Ingelheim Vetmedica Gmbh Formulación de comprimidos farmacéuticos para el sector médico veterinario, método de producción y uso de los mismos
WO2013185284A1 (en) 2012-06-12 2013-12-19 Abbott Laboratories Pyridinone and pyridazinone derivatives
HRP20251029T1 (hr) 2013-07-19 2025-10-24 Boehringer Ingelheim Vetmedica Gmbh Konzervirani eterificirani derivati ciklodekstrina koji sadrže tekući vodeni farmaceutski pripravak
PL3106150T3 (pl) 2013-12-04 2022-01-03 Boehringer Ingelheim Vetmedica Gmbh Ulepszone kompozycje farmaceutyczne pimobendanu
WO2017070708A1 (en) 2015-10-23 2017-04-27 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
DK3423440T3 (da) * 2016-03-04 2021-03-15 Otsuka Pharma Co Ltd 5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-on-derivat til behandlingen af hjernetumorer
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
EP3442972B1 (en) 2016-04-15 2020-03-04 AbbVie Inc. Bromodomain inhibitors
CN113474337A (zh) 2018-12-19 2021-10-01 奥瑞生物药品公司 作为fgfr抑制剂用于治疗癌症的7-((3,5-二甲氧基苯基)氨基)喹喔啉衍生物
US12180207B2 (en) 2018-12-19 2024-12-31 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1488330A (en) * 1973-12-19 1977-10-12 Smith Kline French Lab Dihydropyridazinones
US4111935A (en) * 1975-01-02 1978-09-05 Smith Kline & French Laboratories Limited 3-chloro-6-phenylpyridazine compounds
DE2609645A1 (de) * 1976-03-09 1977-09-15 Boehringer Sohn Ingelheim Aminoalkylheterocyclen
DE3023369A1 (de) * 1980-06-23 1982-01-14 Boehringer Mannheim Gmbh, 6800 Mannheim Aryloxypropanolamine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB8323553D0 (en) * 1983-09-02 1983-10-05 Smith Kline French Lab Pharmaceutical compositions
JPS6193169A (ja) * 1984-10-12 1986-05-12 Sankyo Co Ltd ピリダジノン誘導体及びその製法
DE3934436A1 (de) * 1989-06-01 1991-04-18 Thomae Gmbh Dr K 2-hydroxy-n-propylamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5641783A (en) * 1993-11-12 1997-06-24 Cell Therapeutics, Inc. Substituted amino alcohol compounds
US5827893A (en) * 1996-03-29 1998-10-27 Lurie; Keith G. Mechanical and pharmacological therapies to treat cardiac arrest
MXPA05005661A (es) * 2002-11-27 2005-11-23 Artesian Therapeutics Inc Compuestos con actividad antagonista o antagonista parcial mixta inhibidora de fosfodiesterasa y beta-adrenergica para el tratamiento de insuficiencia cardiaca.
MXPA05006975A (es) * 2002-12-23 2005-12-14 Artesian Therapeutics Inc Compuestos cardiotonicos con actividad inhibidora en contra de receptores beta-adrenergicos y fosfodiesterasa.
EP2015751A2 (en) * 2006-04-28 2009-01-21 Northwestern University Salts of pyridazine compounds

Also Published As

Publication number Publication date
JP2008521806A (ja) 2008-06-26
WO2006060127A3 (en) 2007-03-15
US20080090827A1 (en) 2008-04-17
EP1830852A2 (en) 2007-09-12
WO2006060127A2 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
CA2588949A1 (en) Compounds with mixed pde-inhibitory and .beta.-adrenergic antagonist or partial agonist activity for treatment of heart failure
CA2588947A1 (en) Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase
KR101593253B1 (ko) 페닐 및 벤조디옥시닐 치환 인다졸 유도체
US11091421B2 (en) Benzene fused heterocyclic derivative and pharmaceutical composition comprising the same
PL171933B1 (pl) Sposób wytwarzania nowych amidów PL PL PL
CA2176668C (fr) Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
WO2004050657A2 (en) COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE
KR20070122224A (ko) Mglur5 수용체 친화도를 갖는 페닐아세틸렌 유도체
EP1575923A2 (en) CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST &bgr;-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE
US4598077A (en) Amidine derivatives and cardiotonic compositions
JP7478251B2 (ja) イオンチャネルアンタゴニスト/遮断剤およびその用途
CN117229259A (zh) 一种8-喹啉磺酰胺苯基咪唑类化合物及其应用
EP0419286A2 (en) Pyridone nitriles useful in treating cardiovascular disease
KR102114389B1 (ko) 신규 소듐채널 저해 화합물, 이의 제조방법, 및 이를 포함하는 소듐채널 관련 질환의 예방 또는 치료용 약학적 조성물
EP0220104A2 (fr) Dérivés d'amino-5 pentanenitrile, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent
WO2020003119A1 (en) Compounds and methods for treatment of hedgehog pathway associated conditions
HK40011041B (en) Modulators of the prostacyclin (pg12) receptor useful for the treatment of disorders related thereto
HK40018543B (zh) 芳香族化合物及其药物组合物和用途

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20101108